Evaluation of endometrial changes and p53 expression in tamoxifen treated women: Comparison of various methods

Kathmandu University Medical Journal

Volumn 4 NO. 2, Issue 14, 2006, Pages 145-151

  Pokharel, H P ^a   Bhatla, N ^c   Kriplani, A ^c   Mukhopadhyay, A ^b   Srivastava, A ^c   Ralhan, R ^c  

^a B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Endometrium; Hysteroscopy; p53; Sonography; Sonohysterography; Tamoxifen

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIAL DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTEROSCOPY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREVALENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STANDARD; SYMPTOMATOLOGY; TRANSVAGINAL ECHOGRAPHY;

EID: 33746688644     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Davidson NE. Tamoxifen- Panacea or Pandora's Box? New Engl J Med 1992; 326:885-886.
2. Delhi Cancer Registry, IRCH, Biennial Report 1998 and 1999.
3. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989; 1:117-119.
4. Deligdisch L, Kalir T, Cohen CJ, De Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000, 78: 181-186.
5. Bese T, Kosebay D, Demirkiran F, Arvas M, Bese N, Mandel N. Ultrasonographic appearance of endometrium in post menopausal breast-cancer patients receiving tamoxifen. Eur J Obstet Gynecol Reprod Biol 1996; 67: 157-162.
6. Elhelw B, Ghorab MNM, Farrag SH. Saline sonohysterography for monitoring asymptomatic postmenopausal breast cancer patients taking tamoxifen. Int J Gynecol Obstet 1999; 67: 81-86.
7. Timmerman D, Depest J, Bourne T, van den Berghe I, Collins WP, Vergote I. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 1998; 179:62-70
8. Love CDB, Muir BB, Scrimgeour JB, Leonard RCF, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050-2054.
9. Hemminski K, Rajaniemi H, Lindahl B, Mobergec B. Tamoxifen induced DNA adducts in endometrial samples from breast cancer patients. Cancer Research 1996;56:4374-4377.
10. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000 ; 13: 295-308.
11. Kuwashima Y, Kurosumi M, Kobayashi Y, Tanuma J, Suemasu K, Higashi Y, et al. Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma. Int J Gynecol Pathol 1998; 17:135-139.
12. Ben-Hur H, Berman L, Sandler B, Smirnoff P, Gurevich P, Open M, Zuspan I. Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: A comparative study. Eur J Gynaecol Oncol 1997; 18:400-406.
13. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60: 1777-1788.
14. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T, et al. Endometrial changes in post menopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660-64.
15. Cohen I, Tepper R, Rosen DJ, Shapira J, Cordoba M, Dror Y, et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal treated breast cancer patients does not cause aggravation of endometrial pathology. Gynecol Oncol 1994; 55:138-143.
16. Kedar RP, Bourne TH, Powels TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovarian of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994; 343: 1318-1321.
17. Cohen I, Altaras MM, Shapia J, Tepper R, Rosen DJ, Cordoba M, et al. Time dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996; 15: 152-157.
18. Mourtis MJE, van der Zu AGJ, Willewse PHB. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in post-menopausal breast cancer patients using tamoxifen. Gynecol Oncol 1999; 73: 21-26
19. Cohen I, Perel E, Flex D, Tepper R, Altaras MM, Mario C, et al. Endometrial pathologies in post-menopausal tamoxifen treatment: comparison between gynecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999; 52: 278-282.
20. Cohen I, Beyth Y, Tepper R. The role of ultrasound in the detection of endometrial pathology in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. Obstet Gynecol Surv. 1998; 53: 429-438.
21. Bertelli G, Valenzano M, Costantini S, Rissone R, Augidini C, Signorini A, Gustarino C. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Gynecol Oncol 2000; 78: 275-277.
22. Hann LE, Kim CM, Gonen M, Barakat R, Choi PH, Bach AM. Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen treated women. J Ultrasound Med. 2003; 22: 1192-9.
23. Neven P, Demuylder X, Van Belle Y, Van-Hoof J, Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 1998; 351: 36- .
24. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. Her -2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995; 85: 729-734.
25. Barbati A, Miuni L, Porpora MG, Anceschi M, Collini P, Lauro V, Cosmi EV. Serum evaluation of p53 protein in patients with gynecological cancer. Anticancer Res 2000; 20: 1033-1035.